A TREATMENT PROTOCOL FOR PATIENTS CONTINUING FROM A PRIOR SU011248 PROTOCO
- Conditions
- Patients with any malignancy who have previously been evaluated in a SU001248 protocol
- Registration Number
- EUCTR2005-005335-94-NL
- Lead Sponsor
- Pfizer BV
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1. Partecipated ina previous SU011248 protocol and are judged by the investigator
to have the potential to derive clinical benefit from SU011248 treatment
2. Signed and dated informed consent document indicating that the patient (or
legally acceptable representative) has been informed of all the pertinent aspects
of the trial prior to enrollment.
3. Enrollment within 8 weeks from their last dose of SU011248 or placebo in their
previous study.
4. Willingness and ability to comply with scheduled visits, treatment plans and
laboratory tests and other study procedures.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Subjects presenting with any of the following will not be included in the trial:
1. Current treatment in another clinical trial
2. Pregnancy or breastfeeding
3. Severe acute or chronic medical or psychiatric condition, or laboratory
abnormality that would impart, in the judgment of the investigator, excess risk
associated with study participation or study drug administration, or which, in the
judgment of the investigator, would make the patient inappropriate for entry
into this study
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method